S-1/A: Moleculin Biotech Seeks Up to $7 Million in Public Offering to Advance Cancer Drug Pipeline

Moleculin Biotech is offering up to 2,978,723 shares of common stock along with warrants in a best efforts offering to fund clinical development of its cancer and antiviral drug portfolios.

Summary

• Moleculin Biotech has filed an S-1/A registration statement for a proposed public offering.
• The offering includes up to 2,978,723 shares of common stock, Series A and Series B warrants to purchase up to 2,978,723 shares each, and placement agent warrants.
• Pre-funded warrants are also being offered to certain purchasers who would otherwise exceed beneficial ownership limits.
• The assumed combined public offering price is $2.35 per share and warrants, based on the closing price of MBRX on August 13, 2024.
• The company intends to use the net proceeds, estimated at $6.2 million, to advance its Annamycin and other drug portfolios through clinical development, preclinical studies, and for working capital.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
• The offering is a 'best efforts' offering, meaning there is no guarantee all securities will be sold.
• The Series A warrants will expire on the earlier of (i) two years from the initial exercise date, or (ii) 60 days from our public announcement that we have achieved the Series A Milestone Event.
• The Series B warrants will expire on the earlier of (i) five years from the initial exercise date, or (ii) six months from our public announcement that we have achieved the Series B Milestone Event.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The announcement is a standard capital raise to fund operations. While the company has promising drug candidates, the offering also carries risks of dilution and market volatility.

Positives

• The offering aims to raise capital to advance promising drug candidates through clinical development.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory AML, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma.
• Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory AML from the European Medicines Agency.
• The company has plans for a Phase 3 MIRACLE trial for Annamycin in R/R AML.

Negatives

• The offering is a 'best efforts' offering, meaning there is no guarantee all securities will be sold, potentially reducing the amount of proceeds received.
• Investors may experience immediate and substantial dilution in net tangible book value.
• There is no established public trading market for the common warrants or pre-funded warrants.
• The actual public offering price per share and common warrant and the actual public offering price per pre-funded warrant and common warrant will be determined between us, the placement agent and the investors based on market conditions at the time of pricing, and may be at a discount to the current market price of our common stock.

Risks

• The company has broad discretion in how it uses the proceeds of the offering and may not use these proceeds effectively.
• The market price of the company's common stock could be subject to wide fluctuations.
• If the company is required to obtain Warrant Stockholder Approval, until the company is able to receive such approval the common warrants will not be exercisable, and if the company is unable to obtain such approval the common warrants will have no value.
• The company will require additional capital funding, the receipt of which may impair the value of the company's common stock.
• Purchasers in this offering may experience immediate and substantial dilution in net tangible book value.
• There is no public market for the common warrants or pre-funded warrants being offered in this offering.
• The common warrants are speculative in nature.
• The company may be required to repurchase the common warrants, which may prevent or deter a third party from acquiring the company.
• The company will require substantial additional funding, which may not be available to the company on acceptable terms, or at all, and, if not so available, may require the company to delay, limit, reduce or cease its operations.

Future Outlook

The company plans to advance Annamycin and its other drug portfolios through clinical development, advancing the remainder of the existing portfolio through preclinical studies and into INDs or their equivalent, sponsoring research at MD Anderson and HPI, and for working capital.

Industry Context

The company is operating in the competitive pharmaceutical industry, focusing on oncology and virology. The success of the company depends on the clinical trial results and regulatory approvals.

Comparison to Industry Standards

• It is difficult to compare Moleculin Biotech directly to industry standards without detailed financial benchmarks and clinical trial data.
• Comparable companies in the clinical-stage pharmaceutical sector include those focused on similar therapeutic areas (oncology, virology) and stages of development (Phase 2, Phase 3).
• Companies like Celldex Therapeutics, or Mustang Bio, which are also clinical-stage companies, could be considered for comparison, focusing on metrics like cash runway, clinical trial progress, and market capitalization.
• However, a detailed comparison would require a deeper dive into the specifics of their pipelines, trial designs, and financial positions.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees' stock options may be affected by the change in stock price.
• The capital raise aims to fund the development of new drugs, potentially benefiting patients.
• The company's suppliers and creditors may benefit from the increased financial stability.

Next Steps

• Begin contracting with MIRACLE trial sites in 2024 2H.
• First subject treated in MIRACLE trial in 2025 Q1.
• Interim data (n=75) unblinded and Optimum Dose set for MIRACLE trial in Mid 2026.
• Begin enrollment of 3rd line subjects in MIRACLE2 in 2026.
• Enrollment ends in 2nd line subjects in 2027.
• Final Data for 2nd line subjects in MIRACLE in 2028.
• Begin submission of a new drug application (NDA) the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE in 2028 2H.

Key Dates

Keywords

public offering, common stock, warrants, Annamycin, clinical development, Moleculin Biotech, MBRX, capital raise, pharmaceutical, cancer, AML